Apellis Board Unanimously Recommends Biogen's $5.6B Acquisition Offer at $41/Share Plus CVR

summarizeSummary

Apellis Pharmaceuticals' Board of Directors has unanimously recommended Biogen's offer to acquire the company for approximately $5.6 billion, including $41 per share in cash and a Contingent Value Right.

check_boxKey Events

• Acquisition Agreement Announced

  Biogen Inc. has entered into a definitive agreement to acquire Apellis Pharmaceuticals, Inc. through a tender offer.

• Offer Price and Structure

  Shareholders will receive $41.00 per share in cash, plus one Contingent Value Right (CVR) per share, which offers potential additional cash payments based on future global sales thresholds for SYFOVRE.

• Total Transaction Value

  The acquisition is valued at approximately $5.6 billion, representing a significant premium to Apellis's recent trading levels.

• Unanimous Board Recommendation

  Apellis's Board of Directors has unanimously determined that the transaction maximizes value for shareholders and recommends that shareholders tender their shares.

auto_awesomeAnalysis

This filing formally announces and recommends the acquisition of Apellis Pharmaceuticals by Biogen Inc. for approximately $5.6 billion. The offer of $41 per share in cash, coupled with a Contingent Value Right (CVR) for potential additional payments based on SYFOVRE sales, represents a substantial premium to Apellis's recent trading prices and is slightly above its 52-week high. The unanimous recommendation by Apellis's Board of Directors signals strong confidence in the deal's value for shareholders. This acquisition is a thesis-altering event, as it fundamentally changes the future of Apellis, integrating its assets and pipeline into Biogen's larger structure. Investors should monitor the tender offer process and regulatory clearances, with the transaction expected to close in Q2 2026.